CD8A and neoplasm: Cancer immunity mainly relies on CD8+ cytotoxic T lymphocytes (CTLs); tumor-specific CTLs proliferate and are directed to tumor sites, where they attack cancer cells due to professional APC (pAPC) cross-priming of naive CD8+ T cells [129].